857 Spam-Free Article(s) Found
Symbol Name Last Close Mkt Cap DailyStocks'
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Thursday’s Close
MRK Merck & Company, Inc. $70.42 $187.28B N/A
Article Searches
Gilead's HCV Drug Epclusa Gets Regulatory Nod in Canada http://www.zacks.com/stock/news/223633/gileads-hcv-drug-epclusa-gets-regulatory-nod-in-canada?cid=CS-ZC-FT-223633 Jul 15, 2016 - Gilead (GILD) received a Notice of Compliance from Health Canada for Epclusa for the treatment of adults with genotype 1-6 chronic HCV infection.
Merck & Co. (MRK) Kenneth C. Frazier on Q1 2016 Results - Earnings Call Transcript http://seekingalpha.com/article/3971837-merck-and-co-mrk-kenneth-c-frazier-q1-2016-results-earnings-call-transcript?source=feed_all_articles May 05, 2016 - Merck & Co., Inc. (NYSE:MRK)Q1 2016 Earnings CallMay 05, 2016 8:00 am ETExecutivesTeri Loxam - Vice President, Investor RelationsKenneth C. Frazier - Chairman, President & Chief Executive OfficerRober
Merck & Co (MRK) Q4 2015 Results - Earnings Call Webcast http://seekingalpha.com/article/3858646-merck-and-co-mrk-q4-2015-results-earnings-call-webcast?source=feed_all_articles Feb 03, 2016 -
Stock Market News for September 23, 2015 http://www.zacks.com/stock/news/191065/stock-market-news-for-september-23-2015?cid=CS-ZC-FT-191065 Sep 23, 2015 - Selloff in commodity, auto and biotech stocks dragged benchmarks lower on Tuesday
ANI Pharmaceuticals Inks Deal with Merck for 2 NDAs http://www.zacks.com/stock/news/190989/ani-pharmaceuticals-inks-deal-with-merck-for-2-ndas?cid=CS-ZC-FT-190989 Sep 22, 2015 - ANI Pharmaceuticals (ANIP) announced that it has agreed to acquire two NDAs from Merck (MRK) for $75 million in cash and a percentage of future net sales.
Inovio Gets Grant for Ebola Drugs, Regeneron Inks Deal http://www.zacks.com/stock/news/190985/inovio-gets-grant-for-ebola-drugs-regeneron-inks-deal?cid=CS-ZC-FT-190985 Sep 22, 2015 - Inovio Pharmaceuticals, Inc. (INO) announced that the U.S. Defense Advanced Research Projects Agency has exercised its option to provide an additional $24 million for the development of Inovio's multiple treatment and prevention approaches against Ebola.
Company News for September 22, 2015 http://www.zacks.com/stock/news/190890/company-news-for-september-22-2015?cid=CS-ZC-FT-190890 Sep 22, 2015 - Companies in the News are: ATML,P,ANIP,MRK,VLKAY
Merck Reports Encouraging Phase III Data on Bezlotoxumab http://www.zacks.com/stock/news/190808/merck-reports-encouraging-phase-iii-data-on-bezlotoxumab?cid=CS-ZC-FT-190808 Sep 21, 2015 - Merck & Co. Inc. (MRK) announced encouraging data from two pivotal phase III clinical studies for its investigational antitoxin bezlotoxumab for prevention of recurrence of Clostridium difficile infection.
Tetraphase's (TTPH) Antibiotic Fails in Phase III Study http://www.zacks.com/stock/news/189508/tetraphases-ttph-antibiotic-fails-in-phase-iii-study?cid=CS-ZC-FT-189508 Sep 09, 2015 - Tetraphase Pharmaceuticals (TTPH) announced that the IGNITE2 study on eravacycline for complicated urinary tract infections did not meet its primary endpoint.
Incyte & Hengrui to Develop Anti-PD-1 Monoclonal Antibody http://www.zacks.com/stock/news/188899/incyte-hengrui-to-develop-anti-pd-1-monoclonal-antibody?cid=CS-ZC-FT-188899 Sep 03, 2015 - Incyte (INCY) signs an agreement with Hengrui to develop and commercialize an anti-PD-1 monoclonal antibody, SHR-1210.

Pages: 1...80818283848586

<<<Page 85